[1]戴亦娴,张晓鸣,华 丰,等.白芍总苷调节磷脂酰肌醇3-激酶/蛋白激酶B信号通路对大鼠原发性痛经的改善作用实验研究[J].陕西医学杂志,2024,(8):1021-1025.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.003]
　DAI Yixian,ZHANG Xiaoming,HUA Feng,et al.Improvement effect of total glucosides of paeony on primary dysmenorrhea in rats by regulating PI3K/Akt signaling pathway[J].,2024,(8):1021-1025.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.003]
点击复制

白芍总苷调节磷脂酰肌醇3-激酶/蛋白激酶B信号通路对大鼠原发性痛经的改善作用实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年8期
页码:
1021-1025
栏目:
基础研究
出版日期:
2024-08-05

文章信息/Info

Title:
Improvement effect of total glucosides of paeony on primary dysmenorrhea in rats by regulating PI3K/Akt signaling pathway
作者:
戴亦娴; 张晓鸣; 华 丰; 刘产明; 朱月琴; 蒋 婷; 周 甜; 吴栋才
(常州市中医医院药学部,江苏 常州 213000)
Author(s):
DAI Yixian; ZHANG Xiaoming; HUA Feng; LIU Chanming; ZHU Yueqin; JIANG Ting; ZHOU Tian; WU Dongcai
(Department of Pharmacy,Changzhou Hospital of Traditional Chinese Medicine,Changzhou 213000,China)
关键词:
原发性痛经;  白芍总苷;  磷脂酰肌醇3-激酶;  蛋白激酶B;  大鼠
Keywords:
Primary dysmenorrhea;  Total glucosides of paeony;  Phosphatidylinositol 3-kinase;  Protein kinase B;  Rats
分类号:
R -33
DOI:
DOI:10.3969/j.issn.1000-7377.2024.08.003
文献标志码:
A
摘要:
目的:探讨白芍总苷(TGP)调节磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)信号通路对大鼠原发性痛经(PDM)的改善作用。方法:将雌性SD大鼠采用随机数字表法分为正常对照组(Nor组)、PDM模型组(PDM组)、低剂量TGP组(TGP-L组)、高剂量TGP组(TGP-H组)和高剂量TGP+PI3K激活剂740Y-P组(TGP-H+740Y-P组),每组12只。除Nor组外,其余各组大鼠采用苯甲酸雌二醇联合缩宫素制备大鼠PDM模型,并分别用50、100 mg/kg TGP干预TGP-L组、TGP-H组大鼠,TGP-H+740Y-P组大鼠另需10 mg/kg 740Y-P干预。末次给药后观察大鼠的扭体反应,记录扭体次数和潜伏期,行扭体反应评分。HE染色观察大鼠子宫组织的病理学变化,行病理学评分。ELISA法检测大鼠子宫组织前列腺素F2α(PGF2α)、前列腺素E2(PGE2)水平以及血清β-内啡肽(β-EP)水平。免疫印迹法测量子宫组织PI3K、Akt表达及其磷酸化水平。结果:与Nor组比较,PDM组子宫病理损伤严重,子宫组织病理学评分、PGF2α以及p-PI3K、p-Akt水平升高,子宫组织PGE2及血清β-EP水平降低(均P<0.05)。与PDM组比较,TGP-L组、TGP-H组大鼠扭体反应潜伏期延长,扭体反应次数减少,扭体反应评分降低,子宫组织病理损伤减轻,子宫组织病理学评分、PGF2α以及p-PI3K、p-Akt水平降低,子宫组织PGE2及血清β-EP水平升高(均P<0.05)。高剂量TGP对大鼠PDM的改善作用更显著,而740Y-P减弱了TGP对大鼠PDM的改善作用。结论:TGP可能通过抑制PI3K/Akt信号通路改善大鼠PDM。
Abstract:
Objective:To investigate the improvement effect of total glucosides of paeony(TGP)on primary dysmenorrhea(PDM)in rats by regulating the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)signaling pathway.Methods:Female SD rats were divided into the normal control group(Nor group),PDM model group(PDM group),low-dose TGP group(TGP-L group),high-dose TGP group(TGP-H group)and high-dose TGP+PI3K activator 740Y-P group(TGP-H+740Y-P group)according to random number table method,with 12 rats in each group.Except for the Nor group,rats in other groups were used to prepare rat PDM models using estradiol benzoate combined with oxytocin,and the rats in TGP-L group and TGP-H group were intervened with 50 mg/kg and 100 mg/kg of TGP,respectively.Rats in TGP-H+740Y-P group were additionally intervened with 10 mg/kg of 740Y-P.The torsion reaction of rats was observed after the last administration,and the number of torsion reaction and incubation period were recorded,and the torsion reaction score was performed.HE staining was applied to observe the pathological changes of uterine tissue,and pathological score was performed.ELISA method was applied to detect the levels of prostaglandin F2α(PGF2α),prostaglandin E2(PGE2)in uterine tissue,and β-endorphin(β-EP)in serum.The expression and phosphorylation levels of PI3K and Akt in uterine tissue were measured by Western blot.Results:Compared with Nor group,the pathological injury of uterus in PDM group were serious,the pathological score,the levels of PGF2α,p-PI3K and p-Akt in uterine tissue were increased,while the level of PGE2 in uterine tissue and β-EP in serum were decreased(all P<0.05).Compared with PDM group,TGP-L group and TGP-H group prolonged the incubation period of torsion reaction,reduced the number of torsion reaction,decreased incubation period score,alleviated pathological injury of uterine tissue,and pathological score,the levels of PGF2α,p-PI3K and p-Akt in uterine tissue were decreased,the level of PGE2 in uterine tissue and β-EP in serum were increased(all P<0.05).High dose TGP improved PDM more significantly in rats,and 740Y-P weakened the improvement of TGP on PDM in rats.Conclusion:TGP may improve PDM in rats by inhibiting PI3K/Akt signaling pathway.

参考文献/References:

[1] ITANI R,SOUBRA L,KAROUT S,et al.Primary dysmenorrheal:Pathophysiology,diagnosis,and treatment updates[J].Korean J Fam Med,2022,43(2):101-108.
[2] GUIMARÃES I,PVOA A M.Primary dysmenorrheal:Assessment and treatment[J].Rev Bras Ginecol Obstet,2020,42(8):501-507.
[3] SHARGHI M,MANSURKHANI S M,LARKY D A,et al.An update and systematic review on the treatment of primary dysmenorrhea[J].JBRA Assist Reprod,2019,23(1):51-57.
[4] RISTIANI,ARSYAD A,USMAN A N,et al.The use of aromatherapy in primary dysmenorrhea[J].Gac Sanit,2021,35(Suppl 2):s591-s595.
[5] CARROQUINO-GARCIA P,JIMNEZ-REJANO J J,MEDRANO-SANCHEZ E,et al.Therapeutic exercise in the treatment of primary dysmenorrheal:A systematic review and meta-analysis[J].Phys Ther,2019,99(10):1371-1380.
[6] 李娜,刘孜,李哲,等.基于UPLC-Q-TOF-MS和网络药理学辨识白芍治疗原发性痛经的质量标志物[J].环球中医药,2023,16(8):1516-1525.
[7] JIANG H,LI J,WANG L,et al.Total glucosides of paeony:A review of its phytochemistry,role in autoimmune diseases,and mechanisms of action[J].J Ethnopharmacol,2020,258:112913.
[8] ZHANG L,WEI W.Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony[J].Pharmacol Ther,2020,207(1):107-118.
[9] 沈斯瑶,刘艳,徐鹏刚.白芍总苷联合沙利度胺治疗强直性脊柱炎疗效及对患者活动指标、血清炎性因子水平的影响[J].陕西医学杂志,2020,49(1):20-23.
[10] WANG J,HU K,CAI X,et al.Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis[J].Acta Pharm Sin B,2022,12(1):18-32.
[11] YU L,WEI J,LIU P.Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer[J].Semin Cancer Biol,2022,85:69-94.
[12] XIE Y,QIAN J,LU Q.The therapeutic effect of Ge-Gen decoction on a rat model of primary dysmenorrheal:Label-free quantitative proteomics and bioinformatic analyses[J].Biomed Res Int,2020,2020:5840967.
[13] 郭莎,李雪梅,任奎羽,等.温和灸对原发性痛经模型大鼠子宫微循环及血液流变学的影响[J].世界中医药,2023,18(17):2435-2440.
[14] TANG B,LIU D,CHEN L,et al.NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway[J].J Inflamm(Lond),2020,17:22-32.
[15] 孙燕宁,符梅竹.白芍总苷对腹泻型肠易激综合征大鼠5-HT信号通路的影响[J].西部中医药,2023,36(6):14-18.
[16] 王宏君,孙星星,张润莲.基于PI3K/Akt/NF-κB信号通路探讨升阳益胃汤对肺癌大鼠免疫力的影响[J].天津医药,2023,51(7):739-745.
[17] LPEZ-LIRIA R,TORRES-LAMO L,VEGA-RAMÍREZ F A,et al.Efficacy of physiotherapy treatment in primary dysmenorrheal:A systematic review and meta-analysis[J].Int J Environ Res Public Health,2021,18(15):7832-7843.
[18] 王晓莉,刘慧杰,于增瑞,等.柴附青金汤治疗原发性痛经气滞血瘀证疗效研究[J].陕西中医,2020,41(12):1704-1707.
[19] BARCIKOWSKA Z,RAJKOWSKA-LABON E,GRZYBOWSKA M E,et al.Inflammatory markers in dysmenorrhea and therapeutic options[J].Int J Environ Res Public Health,2020,17(4):1191-1200.
[20] JIANG J,ZHUANG Y,SI S,et al.The association of reproductive hormones during the menstrual period with primary dysmenorrhea[J].Int J Womens Health,2023,15:1501-1514.
[21] ZHANG Y,SU N,LIU W,et al.Metabolomics study of Guizhi Fuling capsules in rats with cold coagulation dysmenorrhea[J].Front Pharmacol,2021,12:764904.
[22] 潘思安,刘余,汪少华,等.基于PI3K/Akt/mTOR信号通路探讨电针治疗原发性痛经大鼠的机制[J].针刺研究,2023,48(12):1258-1265.
[23] 畅秀丽,张安兵.白芍总苷调控NF-κB/NLRP3信号通路对急性痛风性关节炎大鼠的影响机制研究[J].中国免疫学杂志,2023,39(2):313-317.
[24] 包利利,赵达,俞岩,等.白芍总苷对子宫内膜异位症大鼠异位组织HIF-1α/VEGF信号通路的影响[J].中国优生与遗传杂志,2023,31(4):689-695.
[25] LIU R,CHEN Y,LIU G,et al.PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J].Cell Death Dis,2020,11(9):797-808.
[26] 王伊凡,李思远,张姣.右美托咪定预处理通过PI3K/Akt/mTOR信号通路对心肌缺血再灌注大鼠心脏损伤和心肌组织自噬的影响[J].陕西医学杂志,2023,52(10):1299-1303.
[27] 牛丽娜,窦婧,马燕,等.和血柔肝方通过PI3K/Akt/NF-κB信号通路调控自噬相关蛋白改善大鼠肝纤维化机制研究[J].陕西中医,2024,45(2):165-170.
[28] TONG H,YU M,FEI C,et al.Bioactive constituents and the molecular mechanism of curcumae rhizoma in the treatment of primary dysmenorrhea based on network pharmacology and molecular docking[J].Phytomedicine,2021,86:153558.
[29] ZHAO Q,CHENG J,BIAN X,et al.Pharmacokinetics-derived absorbed components responsible for Guizhi-Fuling capsule target PI3K/Akt-Erk to exert an anti-dysmenorrhea effect[J].J Ethnopharmacol,2022,297:115525.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(61970225); 江苏省中医药管理局项目(202232); 江苏省常州市科技计划项目(CJ20229012)
更新日期/Last Update: 2024-08-08